Company Research Report: Know Labs, Inc.

Company Overview

• Name: Know Labs, Inc.

• Mission: Know Labs is committed to making a difference in the lives of millions of people around the world by developing convenient, affordable, non-invasive medical diagnostics solutions, starting with blood glucose monitoring.

• Founded By: Ron Erickson

• Key People:

• Ron Erickson: Founder, Chairman, and CEO

• Dr. James Anderson: Chief Medical Officer

• Pete Conley: Chief Financial Officer and SVP IP

• Leo Trautwein: Chief Commercial Officer

• Dominic Klyve: Chief Science Officer

• Headquarters: 619 Western Ave, Suite 610, Seattle, WA 98104, United States

• Number of Employees: No information is available

• Revenue: No information is available

• Known For: Developing non-invasive medical diagnostic technology, specifically the world's first FDA-cleared non-invasive blood glucose monitor.

Products

1. KnowU

• Type: Non-invasive, wearable continuous blood glucose monitor.

• Description: Designed to assist the management of diabetes and prediabetes without the need for needles or test strips.

• Key Features:

• Continuous and wearable; options for adhesive or wrist/forearm strap.

• Eliminates costly disposables with a rechargeable battery.

• Companion mobile app for real-time glucose tracking.

• Offers affordability, being 3x-5x less expensive than current options.

• Uses RF dielectric spectroscopy for non-invasive monitoring.

Recent Developments

• New Partnerships

• Joined the Wyss Institute for Biologically Inspired Engineering at Harvard University’s Diagnostics Accelerator Program to collaborate on diagnostic technology advancements.

• Events and Milestones:

• Presented insights at the American Diabetes Association’s Scientific Sessions.

• Announced participation in the Wyss DxA Industrial Participant Program to enhance innovation in medical diagnostics.

• Notified about NYSE American Continued Listing Standards.

• Clinical Advancements:

• Ongoing clinical studies to validate the KnowU device using venous blood as a reference.

• Participation of Dr. Virend K. Somers from Mayo Clinic as co-investigator.

• Interim results from studies have shown a stable Mean Absolute Relative Difference (MARD) in glucose estimation.

• Development of machine learning models for accurate blood glucose prediction.

Technology and Intellectual Property

• Platform: Utilizes proprietary radiofrequency dielectric spectroscopy to analyze molecular compositions.

• Intellectual Property: Holding over 270 patents issued, pending, and in-process globally, providing a strategic advantage and a defensible technology moat.

Financial Developments

• Public Offerings:

• Conducted public offerings totaling approximately $5.1 million to support ongoing operations and development efforts.

• Earnings and Financial Reports:

• Reported third-quarter results for FY 2024, maintaining ongoing financial communications through earnings calls and presentations.

Conclusion

Know Labs, Inc. continues to align on its mission to revolutionize diabetes management through non-invasive technology. With ongoing clinical validation and strategic partnerships, the company is positioned to lead innovation in medical diagnostics for diabetes management.